Issue
Alert me when new journal issues are available via or via
Masthead page iii Full-Text PDF (31 KB)
Editorial board page iv Full-Text PDF (65 KB)
TOC pages vii-viii Full-Text PDF (50 KB)
News and Topics
Accrual issues in genitourinary cancer clinical trials Primo N. Lara, Ralph de Vere White pages 379-383 Full Text | Full-Text PDF (78 KB)
Original Articles
Treatment of intermediate-risk prostate cancer with brachytherapy without supplemental pelvic radiotherapy: A review of the H. Lee Moffitt Cancer Center experience Javier F. Torres-Roca, Alan B. Cantor, Sonia Shukla, Michael E. Montejo, Jay Friedland, John D. Seigne, Randy Heysek, Julio Pow-Sang pages 384-390 Abstract | Full Text | Full-Text PDF (138 KB)
Risk of renal insufficiency in African-Americans after radical nephrectomy for kidney cancer David Hepps, Allen Chernoff pages 391-395 Abstract | Full Text | Full-Text PDF (108 KB)
Reduced incidence of bony metastasis at initial prostate cancer diagnosis: Data from CaPSURE™ Charles J. Ryan, Eric P. Elkin, Eric J. Small, Janeen Duchane, Peter Carroll pages 396-402 Abstract | Full Text | Full-Text PDF (110 KB)
Complete response of bony metastatic bladder urothelial cancer to neoadjuvant chemotherapy and cystectomy Fadi N. Joudi, Laila Dahmoush, David M. Spector, Badrinath R. Konety pages 403-406 Abstract | Full Text | Full-Text PDF (387 KB)
A salutary tale of mistaken identity in testicular cancer Ashita Waterston, Morag Seywright, Jeff White pages 407-409 Abstract | Full Text | Full-Text PDF (170 KB)
11C-Acetate positron emission tomography for occult prostate cancer Michael Froehner, Bettina Beuthien-Baumann, Manfred P. Wirth pages 410-411 Abstract | Full Text | Full-Text PDF (135 KB)
Seminar Section Introduction
The status of cancer vaccine therapies in urology Ronald Rodriguez page 412 Full Text | Full-Text PDF (43 KB)
Seminar Articles
Basic overview of current immunotherapy approaches in urologic malignancy Charles G. Drake pages 413-418 Abstract | Full Text | Full-Text PDF (106 KB)
Granulocyte-macrophage colony-stimulating factor−transduced allogeneic cancer cellular immunotherapy: The GVAX® vaccine for prostate cancer Jonathan W. Simons, Natalie Sacks pages 419-424 Abstract | Full Text | Full-Text PDF (300 KB)
Autologous renal cell cancer vaccines using heat shock protein-peptide complexes Maryam Aalamian, Ephraim Fuchs, Renu Gupta, Daniel L. Levey pages 425-433 Abstract | Full Text | Full-Text PDF (132 KB)
Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells Amy M. Lin, Robert M. Hershberg, Eric J. Small pages 434-441 Abstract | Full Text | Full-Text PDF (114 KB)
Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer R. Houston Thompson, James P. Allison, Eugene D. Kwon pages 442-447 Abstract | Full Text | Full-Text PDF (600 KB)
Future directions for vaccine-based therapies Johannes Vieweg pages 448-455 Abstract | Full Text | Full-Text PDF (159 KB)
Survey section editorial board page 456 Full-Text PDF (37 KB)
Urologic Oncology Survey
Health outcomes in older men with localized prostate cancer: Results from the Prostate Cancer Outcomes Study: Hoffman RM, Barry MJ, Stanford JL, Hamilton AS, Hunt WC, Collins MM, Medicine Service, New Mexico VA Health Care System, Albuquerque, NM David F. Penson page 457 Abstract | Full Text | Full-Text PDF (53 KB)
Pilot intervention to enhance sexual rehabilitation for couples after treatment for localized prostate carcinoma: Canada AL, Neese LE, Sui D, Schover LR, Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, TX David F. Penson page 458 Abstract | Full Text | Full-Text PDF (37 KB)
Quality of life in prostate cancer patients taking androgen deprivation therapy: Dacal K, Sereika SM, Greenspan SL, School of Medicine, University of Pittsburgh, Pittsburgh, PA David F. Penson pages 458-459 Abstract | Full Text | Full-Text PDF (42 KB)
Quality of life in long-term survivors of bladder cancer: Allareddy V, Kennedy J, West MM, Konety BR, Department of Urology, University of Iowa, Iowa City, IA David F. Penson pages 459-460 Abstract | Full Text | Full-Text PDF (41 KB)
Mortality after major surgery for urologic cancers in specialized urology hospitals: are they any better? Konety BR, Allareddy V, Modak S, Smith B, Department of Urology, Carver College of Medicine and College of Public Health, University of Iowa, Iowa City, IA David F. Penson page 460 Abstract | Full Text | Full-Text PDF (35 KB)
Combination B7-Fc fusion protein treatment and Treg cell depletion therapy: Liu A, Hu P, Khawli LA, Epstein AL, Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA Joel W. Slaton page 461 Abstract | Full Text | Full-Text PDF (38 KB)
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer: Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B, Czernin J, Sawyers CL, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA Joel W. Slaton pages 461-462 Abstract | Full Text | Full-Text PDF (43 KB)
Targeted chemotherapy with cytotoxic bombesin analogue AN-215 can overcome chemoresistance in experimental renal cell carcinomas: Keller G, Schally AV, Nagy A, Halmos G, Baker B, Engel JB, Endocrine, Polypeptide, and Cancer Institute, Veterans Affairs Medical Center, New Orleans, LA Joel W. Slaton pages 462-463 Abstract | Full Text | Full-Text PDF (42 KB)
Targeted delivery of the ErbB2/HER2 tumor antigen to professional APCs results in effective antitumor immunity: Rohrbach F, Weth R, Kursar M, Sloots A, Mittrucker HW, Wels WS, Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus, Frankfurt am Main, Germany Joel W. Slaton page 463 Abstract | Full Text | Full-Text PDF (36 KB)
Inhibition of cyclooxygenase-2 disrupts tumor vascular mural cell recruitment and survival signaling: Lee A, Frischer J, Serur A, Huang J, Bae JO, Kornfield ZN, Eljuga L, Shawber CJ, Feirt N, Mansukhani M, Stempak D, Baruchel S, Bender JG, Kandel JJ, Yamashiro DJ, Department of Pediatrics, College of Physicians and Surgeons of Columbia University, New York, NY Joel W. Slaton pages 463-464 Abstract | Full Text | Full-Text PDF (41 KB)
Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors: Gurova KV, Hill JE, Guo C, Prokvolit A, Burdelya LG, Samoylova E, Khodyakova AV, Ganapathi R, Ganapathi M, Tararova ND, Bosykh D, Lvovskiy D, Webb TR, Stark GR, Gudkov AV, Department of Molecular Genetics, The Cleveland Clinic Foundation, Cleveland, OH Joel W. Slaton page 464 Abstract | Full Text | Full-Text PDF (34 KB)
Information for Authors page CO3 Full-Text PDF (35 KB)
Copyright © 2010 Elsevier, Inc. All rights reserved | Privacy Policy | Terms & Conditions | Feedback | About Us | Help | Contact Us | The content on this site is intended for health professionals.
